The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
Study Type
OBSERVATIONAL
Enrollment
834
Overall severity of the clinical picture rated on a 4- point scale
Time frame: after 3 and 6 weeks
Assessment of efficacy by investigator on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of efficacy by patient on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of tolerability by investigator on a 4-point scale
Time frame: after 3 and 6 weeks
Assessment of tolerability by patient on a 4-point scale
Time frame: after 3 and 6 weeks
Number of patients with adverse drug reactions
Time frame: up to 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.